SCLC
Conditions
Interventions
ES-SCLC patients:NA
Sponsors
Jilin Provincial Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1 Voluntarily participate and sign the informed consent form. 2 The age of the first use of troxil is = 18 years old, regardless of gender. 3 It was confirmed by histology or cytology as a patient with extensive small cell lung cancer. 4 It is suitable to be treated with troxilide combined with chemotherapy.
Exclusion criteria
Exclusion criteria: 1 Patients are currently participating in other interventional clinical studies. 2 During the treatment with troxil, the patients received systemic chemotherapy other than the standard 4 of the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Taking the incidence of severe neutropenia (SN) as an index, the bone marrow protective effect of troxil in Chinese patients with ES-SCLC was observed.; | — |
Secondary
| Measure | Time frame |
|---|---|
| To observe the bone marrow protective effect of troxil in Chinese patients with ES-SCLC by hematological indexes and supportive therapy.;To observe the safety of troxil in Chinese patients with ES-SCLC by dose adjustment and incidence of adverse events.;Objective remission rate, progression-free survival time and overall survival time were used as indicators to observe the effect of trachloril on the anti-tumor efficacy of combined chemotherapy in Chinese patients with ESSCLC.; | — |
Countries
CHINA
Contacts
Public ContactYing Cheng
Jilin Cancer Hospital
Outcome results
None listed